Welcome to our dedicated page for PharmChem news (Ticker: PCHM), a resource for investors and traders seeking the latest updates and insights on PharmChem stock.
The PharmChem, Inc. (PCHM) news page on Stock Titan aggregates company announcements and press releases related to its role in the medical laboratories industry and its focus on sweat patch drug testing. PharmChem has described itself as a leading provider of sweat patches to detect drugs of abuse and has issued detailed communications about its operations, governance, and corporate transactions.
News items include updates on strategic alternatives, such as the board’s decision to explore options including a sale of the company, mergers, acquisitions, or a debt-financed special dividend. Subsequent releases cover PharmChem’s entry into a definitive agreement to be acquired by Alcohol Monitoring Systems, Inc., including the cash consideration per share and the board’s unanimous approval of the transaction. Later news reports shareholder approval of this acquisition and the expected timing of closing, marking a significant transition in PharmChem’s corporate status.
Other historical news covers topics such as a modified Dutch auction tender offer for PharmChem’s common stock, where the board authorized the repurchase of up to a specified aggregate amount of shares within a defined price range. Governance-related communications, including responses to opposition proxy slates, provide insight into the company’s view of its business model, risk management approach, and the experience of its board and management in forensic drug testing using sweat.
By reviewing this news feed, readers can see how PharmChem has communicated about its sweat patch drug testing business, its risk considerations, capital allocation decisions, and the process that led to its acquisition by Alcohol Monitoring Systems, Inc. Investors and researchers can use this archive to understand the company’s historical decisions and corporate trajectory.
PharmChem (OTC: PCHM) announced that shareholders have approved its acquisition by Alcohol Monitoring Systems, Inc. at a special meeting held on August 27, 2025. According to the agreement terms, PharmChem shareholders will receive $3.75 per share in cash consideration.
The transaction is expected to be finalized at the close of business on August 28, 2025. The company has provided contact information for shareholders with specific questions regarding the acquisition.
PharmChem (OTC: PCHM), a leading provider of sweat patches for drug abuse detection, has announced its acquisition by Alcohol Monitoring Systems, Inc. for $3.75 per share in cash. The deal represents a 22% premium over PharmChem's closing price of $3.07 on January 31, 2025.
The transaction, unanimously approved by PharmChem's board of directors, has already secured support agreements for 52% of outstanding shares. The acquisition is expected to close by the end of Q3 2025, subject to shareholder approval and customary closing conditions. This strategic move aims to expand Alcohol Monitoring Systems' capabilities into drug testing while complementing their existing alcohol and location monitoring technologies portfolio.
PharmChem (OTC: PCHM), a leading provider of sweat patches for drug abuse detection, announced on February 3, 2025, that its Board of Directors has initiated an exploration of strategic alternatives. The company will consider various options including acquisitions, potential sale, merger, or a debt-financed special dividend.
The Board believes PharmChem would be more valuable as part of a larger company and better positioned to serve customers. The company has established a data room for interested parties but has not retained a financial advisor, citing the Board's sufficient experience to guide the process.
The company emphasized there is no guarantee this review will result in any transaction or strategic outcome, and no specific timeline has been set. Further announcements will only be made if the Board approves a specific transaction or if disclosure is legally required.
PharmChem, Inc. (OTC: PCHM) has announced a modified Dutch auction tender offer to repurchase up to $5 million of its common stock at prices between $3.25 and $3.75 per share. Shareholders can tender shares within this price range before the offer expires on May 31, 2022. The board believes this method provides an efficient opportunity for shareholders to sell their shares. However, the offer is subject to certain conditions and does not require a minimum number of shares to be tendered.
PharmChem has responded to a proxy battle initiated by Cedar Creek Partners, urging shareholders to vote for the white proxy card and disregard the opposition's blue card. The company asserts that its current management and board are essential for continued success, citing substantial growth in sales from $769,000 to $6.7 million and an increase in pre-tax income from a loss of $128,000 to $2.1 million since 2005. The opposition's inexperience and intentions to replace key executives could jeopardize the company's progress and relationships within the industry.